Pregled bibliografske jedinice broj: 194798
Current state-of-the-art of concomitant chemoradiation in cervical carcinomas
Current state-of-the-art of concomitant chemoradiation in cervical carcinomas // European journal of gynaecological oncology, 26 (2003), 475-481 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 194798 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Current state-of-the-art of concomitant chemoradiation in cervical carcinomas
Autori
Vrdoljak, Eduard ; Hamm, W.
Izvornik
European journal of gynaecological oncology (0392-2936) 26
(2003);
475-481
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
cervical cancer; concomitant chemoradiotherapy; cisplatin
Sažetak
Despite screening programs, cervical carcinoma remains a major health problem throughout the world. Until recently pelvic radiation has been the standard therapy for advanced disease with overall five-year survival rates of 50%. Recently, five randomized trials demonstrated a significant survival advantage for the concomitant administration of radiotherapy and cisplatin-based chemotherapy. Although the trials vary somewhat in terms of stage of disease, dose of radiation, and schedule of radiation and cisplatin, they all demonstrated a significant survival benefit for the combined approach. Congruent to these findings are results from a meta-analysis based on the data from 19 trials with 4, 580 randomized patients. The absolute increase in progression-free and overall survival was 16% and 12%, respectively. Contrary to these findings is the result of the National Cancer Institute of Canada (NCCI) trial. Despite that result cisplatin-based concomitant chemoradiotherapy has become the standard treatment of locally advanced cervical cancer.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE